New Data Demonstrating Potency of Durata Therapeutics, Inc. ' Dalbavancin Against Bacterial Pathogens Presented at ICAAC 2012  
9/10/2012 9:25:06 AM

SAN FRANCISCO--(BUSINESS WIRE)--Durata Therapeutics (NASDAQ: DRTX) today announced data from an in vitro study and surveillance results of its lead product candidate, dalbavancin, currently under investigation in two ongoing, global, Phase 3 clinical trials for the treatment of acute bacterial skin and skin structure infections (ABSSSI). The data, presented at the 52nd Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC), demonstrate the potency of dalbavancin against numerous significant bacterial isolates in the United States and Europe.